Literature DB >> 23114374

Community outbreak of macrolide-resistant Mycoplasma pneumoniae in Yamagata, Japan in 2009.

Yu Suzuki1, Tsutomu Itagaki, Junji Seto, Akiko Kaneko, Chieko Abiko, Katsumi Mizuta, Yoko Matsuzaki.   

Abstract

BACKGROUND: We detected a community outbreak of macrolide-resistant Mycoplasma pneumoniae infection that occurred predominantly among students at 2 schools in Yamagata, Japan.
METHODS: Throat swab specimens were collected from patients who were clinically suspected to have M. pneumoniae infection after testing negative for influenza virus by a nasopharyngeal swab rapid antigen test. We performed cultures for M. pneumoniae, and all isolates were sequenced for the presence of a mutation of the 23S rRNA gene.
RESULTS: Of 96 specimens collected between July 2009 and January 2010, 83 were from students attending junior high school A and primary schools B, C and D. A total of 47 M. pneumoniae isolates were obtained; among them, 25, 15 and 4 were isolated from students attending schools A, B and D, respectively, and M. pneumoniae could not be isolated from students who attended school C. An A2063T mutation in domain V of the 23S rRNA gene, which is associated with macrolide resistance, was identified in 39 (83.0%) isolates. The rates of macrolide resistance at schools A, B and D were 96.0%, 86.7% and 0%, respectively. The minimum inhibitory concentrations for isolates with an A2063T transversion showed high resistance to clarithromycin (minimum inhibitory concentration, 16-64 mg/L), and clarithromycin prescribed initially was clinically ineffective.
CONCLUSIONS: This school-based cluster of macrolide-resistant M. pneumoniae infections, which was identified in 2 geographically close schools, indicates that the transmission principally occurred by close contact between students at school. Monitoring the spread of macrolide-resistant M. pneumoniae and clinical guidelines for the appropriate medication against such infections would be needed to control outbreaks of M. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23114374     DOI: 10.1097/INF.0b013e31827aa7bd

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  16 in total

1.  Study of Two Separate Types of Macrolide-Resistant Mycoplasma pneumoniae Outbreaks.

Authors:  Yingshuo Wang; Qian Ye; Dehua Yang; Zhimin Ni; Zhimin Chen
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 2.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

3.  In vitro antibacterial activity of α-methoxyimino acylide derivatives against macrolide-resistant pathogens and mutation analysis in 23S rRNA.

Authors:  Hiroyuki Sugiyama; Ippei Yoshida; Mayumi Ueki; Katsuhiko Tanabe; Akira Manaka; Keiichi Hiramatsu
Journal:  J Antibiot (Tokyo)       Date:  2017-01-11       Impact factor: 2.649

4.  Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China.

Authors:  Zibo Zhou; Xiangzhi Li; Xiaojian Chen; Fangjun Luo; Changwang Pan; Xiaoping Zheng; Feng Tan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

5.  Molecular characterizations of PCR-positive Mycoplasma pneumoniae specimens collected from Australia and China.

Authors:  Guanhua Xue; Qinning Wang; Chao Yan; Neisha Jeoffreys; Liqiong Wang; Shaoli Li; Gwendolyn L Gilbert; Hongmei Sun
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

6.  Cluster of macrolide-resistant Mycoplasma pneumoniae infections in Illinois in 2012.

Authors:  Victoria Tsai; Bernard B Pritzker; Maureen H Diaz; Jonas M Winchell; Lauri A Hicks; Brianna Petrone; Alvaro Benitez; Bernard J Wolff; Kenneth L Soyemi
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

7.  Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.

Authors:  David Oldach; Kay Clark; Jennifer Schranz; Anita Das; J Carl Craft; Drusilla Scott; Brian D Jamieson; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

8.  Comparison of pyrosequencing, Sanger sequencing, and melting curve analysis for detection of low-frequency macrolide-resistant mycoplasma pneumoniae quasispecies in respiratory specimens.

Authors:  Kwok-Hung Chan; Kelvin K W To; Betsy W K Chan; Clara P Y Li; Susan S Chiu; Kwok-Yung Yuen; Pak-Leung Ho
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948

9.  Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan.

Authors:  Kentaro Matsuda; Mitsuo Narita; Nobuyuki Sera; Eriko Maeda; Hideaki Yoshitomi; Hitomi Ohya; Yuko Araki; Tatsuyuki Kakuma; Atsushi Fukuoh; Kenji Matsumoto
Journal:  BMC Infect Dis       Date:  2013-12-16       Impact factor: 3.090

10.  Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics.

Authors:  Xijie Liu; Yue Jiang; Xiaogeng Chen; Jing Li; Dawei Shi; Deli Xin
Journal:  Biomed Res Int       Date:  2014-01-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.